drugset
drugset / Trial / NCT05142631

Fruquintinib in the Treatment of Soft Tissue Sarcoma

NCT05142631 ↗

Phase 2 Unknown 31 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy of Fruquintinib in patients with chemotherapy insensitive or chemotherapy resistant soft tissue sarcoma

Timeline

Start
2021-11-21
Primary completion
2023-05-30
Completion
2023-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Fruquintinib Small molecule 5 mg Oral

Indications

soft tissue sarcoma